BECTON, DICKINSON AND COMPANY

BD and Babson Diagnostics expanded their partnership to introduce innovative fingertip blood collection and testing technologies in U.S. health systems, aiming to make blood testing less invasive and more accessible in various care settings, improving patient satisfaction and outcomes.

BD and Babson Diagnostics expand fingertip blood collection and testing technologies for U.S. health systems, integrating BD's MiniDraw™ with Babson's BetterWay to enable testing with six drops of blood, improving access and reducing barriers in underserved areas.

The Zacks Medical - Dental Supplies industry is consolidating in 2024, with stable dental patient traffic but declining discretionary spending on high-cost procedures. Despite macroeconomic challenges, the global dental industry is expected to grow to $95.37 billion by 2032. Companies like BD, McKesson, Cardinal Health, and Merit Medical are showing positive trends. The industry faces challenges from inflation and interest rates but benefits from technological advancements and an aging population increasing demand for dental care.

The Brain Tumor Therapeutics Market is projected to grow from USD 3.28 billion in 2024 to USD 5.28 billion by 2030, driven by advances in healthcare technologies and increased investment in oncology research. Key areas explored include market penetration, development, diversification, competitive assessment, and product innovation. Challenges include high R&D costs and regulatory hurdles. Opportunities lie in personalized medicine and novel drug delivery systems.

Cell Expansion Market to grow at 14.9% CAGR from USD 12.45 billion in 2023 to USD 43.44 billion in 2030, driven by chronic diseases and regenerative medicine. Key players include Thermo Fisher Scientific and Merck KGaA. Asia-Pacific expected to lead growth due to biotech investments.

The Immunohistochemistry Market is projected to grow from USD 3.1 billion in 2023 to USD 5.5 billion by 2031, at a CAGR of 7.4%. Factors driving growth include automation, advanced IHC solutions, and increased demand for personalized medicine. Multiplexed IHC, enabling detailed analysis from a single sample, is a key emerging technology. North America leads in market share due to biotech advancements and high cancer prevalence.

The Business Research Company's report on the Global Lab Automation In Genomics Market forecasts growth from $2.01 billion in 2023 to $4.17 billion in 2028 at a CAGR of 15.7%, driven by precision medicine and automated genomic sequencing technologies.

BD and Hamilton launch robotics-compatible reagent kits for single-cell research, streamlining DNA library preparation and enhancing consistency, efficiency, and throughput in genomic sequencing.

BD invests in Babson Diagnostics to enhance their partnership, aiming to make blood testing more accessible and less invasive with BetterWay™. This innovation uses a small fingertip blood sample for diagnosing chronic conditions, available at Austin pharmacies, offering a convenient, affordable testing experience.

The Global Drug Device Combination Products Market is projected to reach USD 174.4 billion in 2024 and USD 389.7 billion by 2033 at a CAGR of 9.3%. The US market is expected to grow from USD 59.1 billion in 2024 to USD 125.6 billion by 2033 at a CAGR of 8.7%. Key drivers include technological advancements and rising chronic diseases. Major players include Medtronic, Abbott Laboratories, and Boston Scientific.